Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?
Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.
The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
Lessons can be learned from the reality TV shows currently dominating the nation's airwaves.
Some recommendations to help marketers put their best foot forward on smartphone and tablet screens
The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.
The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.
The company plans to spin off its pharmaceutical unit.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
Missed MM&M's Skill Sets Live event on Engaging Patients? We're now giving you a second chance to get up to speed! Click here to access this insightful e-book with all the key take-aways.